Trials / Unknown
UnknownNCT01786473
Testogel® (Testosterone Gel 50mg/5g) in the Treatment of Male Hypogonadism
A Multi-center, Double Blind, Randomized, Placebo Controlled Study of Testogel® (Testosterone Gel 50mg/5g) in the Treatment of Male Hypogonadism
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 240 (estimated)
- Sponsor
- Laboratoires Besins International · Industry
- Sex
- Male
- Age
- 18 Years – 68 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and efficacy of Testogel® 50mg/5g gel administered once daily (QD, morning dosing) compared to placebo administered once daily (QD, morning dosing), for 3 months, in hypogonadal men with testosterone deficiency being confirmed by clinical features and biochemical tests. For men with hypogonadism, treatment aims to restore testosterone levels to normal physiological range.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Testogel 1% | |
| DRUG | Placebo |
Timeline
- Start date
- 2012-12-01
- Primary completion
- 2014-12-01
- First posted
- 2013-02-08
- Last updated
- 2013-02-08
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT01786473. Inclusion in this directory is not an endorsement.